The near-certain trader consensus on no hantavirus vaccine approval or licensure by the end of 2026 stems from the absence of any candidate advancing past early preclinical stages or initial Phase I safety trials. Promising mRNA platforms, including single-dose constructs from UTMB that fully protected hamsters against Andes virus and collaborative efforts with Moderna and Korea University, remain in animal testing or early optimization, with a Korean national sa-mRNA project only launching its two-year preclinical and manufacturing phase in mid-2026. No Phase 3 efficacy studies are underway for this rare rodent-borne pathogen, and historical timelines plus strain diversity make rapid licensure improbable without unprecedented emergency acceleration. Ongoing monitoring of any outbreak-driven funding shifts or trial expansions could still influence late-year developments.